loading page

Therapeutic strategies to fight COVID-19: which is the status artis?
  • +10
  • Cristina Scavone,
  • Annamaria Mascolo,
  • Concetta Rafaniello,
  • Liberata Sportiello,
  • Ugo Trama,
  • Alice Zoccoli,
  • Francesca Bernardi,
  • Giorgio Racagni,
  • Liberato Berrino,
  • Giuseppe Castaldo,
  • Enrico Coscioni,
  • Francesco Rossi,
  • Annalisa Capuano
Cristina Scavone
Università degli Studi della Campania Luigi Vanvitelli
Author Profile
Annamaria Mascolo
Università degli Studi della Campania Luigi Vanvitelli
Author Profile
Concetta Rafaniello
Università degli Studi della Campania Luigi Vanvitelli
Author Profile
Liberata Sportiello
Università degli Studi della Campania Luigi Vanvitelli
Author Profile
Ugo Trama
Regional Pharmaceutical Unit
Author Profile
Alice Zoccoli
Campus Bio-Medico University
Author Profile
Francesca Bernardi
Regional Pharmaceutical Unit
Author Profile
Giorgio Racagni
Università degli Studi di Milano
Author Profile
Liberato Berrino
University of Campania Luigi Vanvitelli
Author Profile
Giuseppe Castaldo
Federico II University Hospital
Author Profile
Enrico Coscioni
Agenzia Nazionale per i Servizi Sanitari Regionali
Author Profile
Francesco Rossi
Università degli Studi della Campania Luigi Vanvitelli
Author Profile
Annalisa Capuano
Università degli Studi della Campania Luigi Vanvitelli
Author Profile

Abstract

COVID-19 is a complex disease and many difficulties are faced today especially in the proper choice of pharmacological treatments. The role of antiviral agents for COVID-19 is still being investigated. The evidence for immunomodulatory and anti-inflammatory drugs is quite conflicting, while the use of corticosteroids is supported by robust evidence. The use of heparins in hospitalized critically ill patients is preferred over other anticoagulants. Lastly, conflicting data were found regarding to the use of convalescent plasma and vitamin D. According to data shared by the WHO, many vaccines are under phase 3 clinical trials and some of them already received the marketing approval in EU countries and in the US. In conclusion, drugs repurposing has represented the main approach recently used in the treatment of patients with COVID-19. At this moment, the analysis of efficacy and safety data of drugs and vaccines used in real life context is strongly needed.

Peer review status:ACCEPTED

13 Jan 2021Submitted to British Journal of Pharmacology
17 Jan 2021Submission Checks Completed
17 Jan 2021Assigned to Editor
18 Jan 2021Reviewer(s) Assigned
31 Jan 2021Review(s) Completed, Editorial Evaluation Pending
01 Feb 2021Editorial Decision: Revise Minor
12 Feb 20211st Revision Received
15 Feb 2021Assigned to Editor
15 Feb 2021Submission Checks Completed
15 Feb 2021Reviewer(s) Assigned
27 Feb 2021Review(s) Completed, Editorial Evaluation Pending
28 Feb 2021Editorial Decision: Revise Minor
01 Mar 20212nd Revision Received
03 Mar 2021Assigned to Editor
03 Mar 2021Submission Checks Completed
04 Mar 2021Review(s) Completed, Editorial Evaluation Pending
05 Mar 2021Editorial Decision: Accept